Construction of oxygen vacancy-rich ZnO@carbon nanofiber aerogels as a free-standing anode for superior lithium storage.

The development of next-generation high-capacity freestanding materials as electrodes in lithium-ion batteries (LIBs) has significant potential. Here, oxygen vacancy-rich ZnO (Ov-ZnO) deposited on carbonized bacterial cellulose (CBC) aerogels is developed via in-situ uniformly growing ZIF-8-NH2 particles on CBC aerogels, followed by the hydrazine reduction and pyrolysis. The CBC serves as a free-standing skeleton to disperse and support ZIF-8-NH2 derived ZnO while the introduction of oxygen vacancies can effectively promote the internal ion/electron transfer. As a result, the obtained free-standing aerogels (Ov-ZnO@CBC) displays a reversible capacity of 710 mAh g-1 at 1 A g-1 after 1000 cycles, which is superior to ZnO@CBC without hydrazine reduction treatment. Furthermore, the assembled Li free-standing full cell using the Ov-ZnO@CBC composite as the anode and BC@LiFePO4 (BC@LFP) as the cathode exhibits an outstanding cycling performance of 150 mAh g-1 after 100 cycles at 0.1 A g-1, displaying satisfactory lithium-ion storage capability. It is noteworthy that both Ov-ZnO@CBC and BC@LFP are obtained in the form of a free-standing aerogel. This work offers a strategy to prepare high-capacity and long-cycle self-supporting aerogel-based electrodes for flexible LIBs.

Selective Catalytic Transfer Hydrogenation of Lignin to Alkyl Guaiacols Over NiMo/Al-MCM-41.

Efficient deoxygenation of lignin-derived bio-oils is central to their adoption as precursors to sustainable liquid fuels in place of current fossil resources. In-situ catalytic transfer hydrogenation (CTH), using isopropanol and formic acid as solvent and in-situ hydrogen sources, was demonstrated over metal-doped and promoted MCM-41 for the depolymerization of oxygen-rich (35.85 wt%) lignin from Chinese fir sawdust (termed O-lignin). A NiMo/Al-MCM-41 catalyst conferred an optimal lignin-derived oil yield of 61.6 wt% with a comparatively low molecular weight (Mw =542 g mol-1 , Mn =290 g mol-1 ) and H/C ratio of 1.39. High selectivity to alkyl guaiacols was attributed to efficient in-situ hydrogen transfer from isopropanol/formic acid donors, and a synergy between surface acid sites in the Al-doped MCM-41 support and reducible Ni/Mo species, which improved the chemical stability and quality of the resulting lignin-derived bio-oils.

Prognostic value of lymphocyte-to-monocyte ratio and systemic immune-inflammation index in non-small-cell lung cancer patients with brain metastases.

Aim: We aimed to evaluate the prognostic values of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR) and systemic immune-inflammation index (SII) in patients with brain metastases from non-small-cell lung cancer (NSCLC). Materials & methods: We conducted Kaplan-Meier analysis and multivariable Cox analysis to evaluate the prognostic values of NLR, PLR, LMR and SII. Results: Kaplan-Meier analysis showed that the patients in low LMR, high NLR, PLR and SII groups were associated with shorter overall survival. Multivariable Cox analysis revealed LMR and SII were independent prognostic factors for overall survival (p = 0.002 and p = 0.004, respectively). Conclusion: LMR and SII are of significant values in clinical prognostic evaluation for patients with brain metastases from NSCLC.

The post-treatment neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after treatment of stage III non-small-cell lung cancer with conventionally fractionated radiotherapy.

Aim: To investigate the predictive potential of post-treatment neutrophil-to-lymphocyte ratio (NLR) and changes in this ratio (ΔNLR) for stage III non-small-cell lung cancer (NSCLC) patients who received conventionally fractionated radiotherapy (CFRT). Patients & methods: The data of 168 NSCLC patients treated at the Shandong Cancer Hospital were analyzed retrospectively. The relationship between progression-free survival (PFS), overall survival (OS) and post-treatment NLR and ΔNLR were analyzed using both Kaplan-Meier and Cox regression methods. Results: Kaplan-Meier survival analyses showed that post-treatment NLR and ΔNLR were associated with PFS (p < 0.001) and OS (p < 0.001) after CFRT. Multivariate analyses revealed that ΔNLR was an independent predictor of PFS (p = 0.001) and OS (p = 0.018). Post-treatment NLR can only be used as an independent predictor of PFS (p = 0.040). Conclusion: Our results demonstrated the prognostic value of the ΔNLR in predicting PFS and OS in stage III NSCLC patients undergoing CFRT. However, post-treatment NLR has predictive value only for PFS.

The predictive effect of the systemic immune-inflammation index for patients with small-cell lung cancer.

Aim: The purpose of this study was to investigate the predictive power of the systemic immune inflammation index (SII) based on neutrophil (N), platelet (P) and lymphocyte (L) on the clinical outcomes of patients with SCLC. Patients & methods: Blood samples of 228 patients were obtained 1 week before treatment to measure the SII (SII = P × N/L). Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier curves and Cox regression models. Results: Higher SII was associated with poorer OS (p < 0.001) and poorer PFS (p < 0.001). Multivariable analyses further revealed SII as an independent prognostic factor for OS (p < 0.001) and PFS (p < 0.001). Conclusion: Pretreatment SII was a valuable prognostic factor for PFS and OS in SCLC patients.

Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer.

Aim: To evaluate the value of pretreatment blood biomarkers in predicting pathologic responses to neoadjuvant chemoradiotherapy (neo-CRT) in patients with locally advanced rectal cancer. Materials & methods: We conducted logistic regression analysis and receiver operating characteristic to assess the predictive value of blood biomarkers. The outcome was defined by the pathologic complete response and good response. Results: Carcinoembryonic antigen (CEA) (p < 0.001), neutrophil-to-lymphocyte ratio (p = 0.024), platelet-to-lymphocyte ratio (p = 0.006) and lymphocyte-to-monocyte ratio (LMR) (p < 0.001) were significant predictors of pathologic complete response, with area under the curve of 0.785, 0.794, 0.740 and 0.913, respectively; CEA (p = 0.007) and LMR (p < 0.001) correlated significantly with good response, with area under the curve of 0.743 and 0.771, respectively. Conclusion: Lower LMR and higher CEA, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before treatment could predict poorer pathologic response to neo-CRT in patients with locally advanced rectal cancer.

Metastatic location of extensive stage small-cell lung cancer: implications for thoracic radiation.

BACKGROUNDS: This study was designed to evaluate the role of thoracic radiotherapy (TRT) in a selected patient population with oligometastatic extensive stage small-cell lung cancer (ES-SCLC) without brain or liver involved. The underlying hypothesis was that TRT will improve outcomes in this favorable patient population. METHODS: 305 patients were included in an institutional review board (IRB)-approved study, of which 105 received TRT after chemotherapy (ChT) and 200 received ChT alone. The survival outcomes were compared between ChT+TRT group and ChT-alone group in patients with oligometastasis without brain or liver involved and patients with brain/liver/multimetastasis, respectively. RESULTS: The 1-year, 2-year and 5-year overall survival (OS) for all patients were 60.3%, 23.9% and 1.6%, respectively. The addition of TRT significantly improved PFS in total patients than ChT alone (14.5 months vs. 10.1 months, p = 0.006), but the OS benefit was not significant (17.8 months vs. 16.5 months, p = 0.061). For patients with oligometastasis (n = 118), TRT offered significant progression free survival (PFS) (16.5 months vs. 9.1 months, p = 0.005) and OS (19.2 months vs. 15.6 months, p = 0.039) benefits. However, for patients with brain/liver/multimetastasis, the PFS and OS were not improved with TRT (p = 0.49, p = 0.811). CONCLUSIONS: TRT provided significant PFS and OS benefits in patients with oligometastatic ES-SCLC without brain or liver involved. The consolidative TRT is a reasonable treatment option for this favorable patient population.